A clinical trial of IV formulation of Selonabant for unintentional cannabis poisoning in childeren

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

03 Oct 2024 New trial record
25 Sep 2024 According to an Anebulo Pharmaceuticals media release, the Company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.
25 Sep 2024 According to an Anebulo Pharmaceuticals media release, the company has received the first tranche of a two year cooperative grant of up to approximately 1.9 million Dollars from the National Institute on Drug Abuse (NIDA), part of the NIH. With this support from NIDA, Anebulo aims to complete IND-enabling activities and the scale up of its IV formulation of selonabant around calendar year end 2024 as it prepares for clinical studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com